Silverfin false false 31/12/2024 01/01/2024 31/12/2024 N A Rowell 06/06/2011 14 July 2025 The principal activity of the company is that of a holding company of its subsidiary companies, VirdisGroup Limited and VirdisGroup S.a.r.l..
The principal activity of the subsidiary companies is that of the provision of recruitment consultancy to the life science industry on a global basis.
07659137 2024-12-31 07659137 bus:Director1 2024-12-31 07659137 2023-12-31 07659137 core:CurrentFinancialInstruments 2024-12-31 07659137 core:CurrentFinancialInstruments 2023-12-31 07659137 core:ShareCapital 2024-12-31 07659137 core:ShareCapital 2023-12-31 07659137 core:RetainedEarningsAccumulatedLosses 2024-12-31 07659137 core:RetainedEarningsAccumulatedLosses 2023-12-31 07659137 core:CostValuation 2023-12-31 07659137 core:CostValuation 2024-12-31 07659137 bus:OrdinaryShareClass1 2024-12-31 07659137 bus:OrdinaryShareClass2 2024-12-31 07659137 2024-01-01 2024-12-31 07659137 bus:FilletedAccounts 2024-01-01 2024-12-31 07659137 bus:SmallEntities 2024-01-01 2024-12-31 07659137 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 07659137 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07659137 bus:Director1 2024-01-01 2024-12-31 07659137 2023-01-01 2023-12-31 07659137 core:Subsidiary1 2024-01-01 2024-12-31 07659137 core:Subsidiary1 1 2024-01-01 2024-12-31 07659137 core:Subsidiary1 1 2023-01-01 2023-12-31 07659137 core:Subsidiary2 2024-01-01 2024-12-31 07659137 core:Subsidiary2 1 2024-01-01 2024-12-31 07659137 core:Subsidiary2 1 2023-01-01 2023-12-31 07659137 core:Subsidiary3 2024-01-01 2024-12-31 07659137 core:Subsidiary3 1 2024-01-01 2024-12-31 07659137 core:Subsidiary3 1 2023-01-01 2023-12-31 07659137 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 07659137 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 07659137 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 07659137 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure decimalUnit xbrli:shares

Company No: 07659137 (England and Wales)

VIRDISPHARMA LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

VIRDISPHARMA LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

VIRDISPHARMA LIMITED

COMPANY INFORMATION

For the financial year ended 31 December 2024
VIRDISPHARMA LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2024
DIRECTOR N A Rowell
REGISTERED OFFICE 22 Wycombe End
Beaconsfield
Buckinghamshire
HP9 1NB
United Kingdom
COMPANY NUMBER 07659137 (England and Wales)
ACCOUNTANT S&W Partners (Thames Valley) Limited
22 Wycombe End
Beaconsfield
Buckinghamshire
HP9 1NB
VIRDISPHARMA LIMITED

BALANCE SHEET

As at 31 December 2024
VIRDISPHARMA LIMITED

BALANCE SHEET (continued)

As at 31 December 2024
Note 2024 2023
£ £
Fixed assets
Investments 3 22,044 22,044
22,044 22,044
Current assets
Debtors 4 127,883 127,883
127,883 127,883
Net current assets 127,883 127,883
Total assets less current liabilities 149,927 149,927
Net assets 149,927 149,927
Capital and reserves
Called-up share capital 5 9,700 9,700
Profit and loss account 140,227 140,227
Total shareholders' funds 149,927 149,927

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of VirdisPharma Limited (registered number: 07659137) were approved and authorised for issue by the Director on 14 July 2025. They were signed on its behalf by:

N A Rowell
Director
VIRDISPHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
VIRDISPHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

VirdisPharma Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 22 Wycombe End, Beaconsfield, Buckinghamshire, HP9 1NB, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with ‘The Financial Reporting Standard applicable in the UK and the Republic of Ireland’ issued by the Financial Reporting Council, including Section 1A of Financial Reporting Standard 102 (FRS102), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The functional currency of VirdisPharma Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Group accounts exemption

Group accounts exemption s399
The Company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the Company as an individual entity and not about its group.

Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Fixed asset investments

2024 2023
£ £
Subsidiary undertakings 22,044 22,044

Investments in subsidiaries

2024
£
Cost
At 01 January 2024 22,044
At 31 December 2024 22,044
Carrying value at 31 December 2024 22,044
Carrying value at 31 December 2023 22,044

Investments in shares

Details of the company's subsidiaries at 31 December 2024 are as follows:

Name of entity Registered office Principal activity Class of
shares
Ownership
31.12.2024
Ownership
31.12.2023
Held
VirdisGroup Limited England and Wales Recruitment consultancy Ordinary 100.00% 100.00% Direct
VirdisGroup SARL Switzerland Recruitment consultancy Ordinary 100.00% 100.00% Direct
VirdisOne Limited England and Wales Dormant Ordinary 100.00% 100.00% Direct

4. Debtors

2024 2023
£ £
Amounts owed by Group undertakings 127,883 127,883

5. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
5,389 Ordinary A shares of £ 1.00 each 5,389 5,389
4,311 B Ordinary shares of £ 1.00 each 4,311 4,311
9,700 9,700

6. Related party transactions

The company is a wholly owned member of the group and as such has taken advantage of the exemption permitted by section 1AC.35 'Related Party Disclosures', not to provide disclosures of transactions entered into with other wholly owned members of the group.